{"id":"rlp2086","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"rLP2086 is a recombinant lipidated protein designed to present meningococcal epitopes in a manner that stimulates both innate and adaptive immune responses. It targets conserved regions of Neisseria meningitidis lipoproteins to provide broad protection against multiple meningococcal serogroups. The vaccine candidate aims to induce bactericidal antibodies and cellular immunity against invasive meningococcal disease.","oneSentence":"rLP2086 is a recombinant lipoprotein that mimics a naturally occurring lipoprotein to activate the immune system against meningococcal bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:31.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease (serogroups A, B, C, W, Y)"}]},"trialDetails":[{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT01299480","phase":"PHASE2","title":"A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03-03","conditions":"Meningococcal Vaccine","enrollment":1714},{"nctId":"NCT01323270","phase":"PHASE2","title":"A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03-18","conditions":"Meningococcal Vaccine, rLP2086, Repevax","enrollment":753},{"nctId":"NCT02534935","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-31","conditions":"Meningococcal B Disease","enrollment":396},{"nctId":"NCT02531698","phase":"PHASE2","title":"A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08","conditions":"MENINGOCOCCAL INFECTION","enrollment":400},{"nctId":"NCT01543087","phase":"PHASE3","title":"Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09-07","conditions":"Meningococcal Infection","enrollment":698},{"nctId":"NCT01461980","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2648},{"nctId":"NCT01768117","phase":"PHASE2","title":"Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Meningitis, Meningococcal, Serogroup B","enrollment":13},{"nctId":"NCT01461993","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2499},{"nctId":"NCT01830855","phase":"PHASE3","title":"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Meningococcal Vaccine","enrollment":3596},{"nctId":"NCT01352845","phase":"PHASE3","title":"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05","conditions":"Healthy","enrollment":3301},{"nctId":"NCT00879814","phase":"PHASE1","title":"Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Meningitis, Meningococcal","enrollment":48},{"nctId":"NCT00808028","phase":"PHASE2","title":"A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Meningitis, Meningococcal","enrollment":538},{"nctId":"NCT01352793","phase":"PHASE3","title":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Meningitis, Meningococcal","enrollment":5715},{"nctId":"NCT00798304","phase":"PHASE2","title":"Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Meningitis, Meningococcal","enrollment":46},{"nctId":"NCT00387725","phase":"PHASE2","title":"Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-11","conditions":"Healthy","enrollment":127},{"nctId":"NCT00780806","phase":"PHASE1, PHASE2","title":"Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-10","conditions":"Meningitis, Meningococcal","enrollment":60},{"nctId":"NCT00387569","phase":"PHASE1","title":"Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Healthy","enrollment":99},{"nctId":"NCT00297687","phase":"PHASE1","title":"Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Meningitis, Meningococcal","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rLP2086","genericName":"rLP2086","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"rLP2086 is a recombinant lipoprotein that mimics a naturally occurring lipoprotein to activate the immune system against meningococcal bacteria. Used for Prevention of invasive meningococcal disease (serogroups A, B, C, W, Y).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}